



SmartPA Criteria

Drug/Drug Class:	Selzentry® Clinical Edit
First Implementation Date:	April 7, 2010
Revised Date:	June 20, 2019
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Selzentry® (maraviroc)

Why was this Issue Selected: Selzentry® (maraviroc) is a CCR5 (C-C chemokine receptor type 5) co-receptor antagonist indicated for the treatment of only CCR5-tropic HIV-1 infection with other antiretroviral agents. In 2016, Selzentry received FDA approval to expand its indication to include treatment of pediatric patients 2 years of age and older. Selzentry works by selectively binding to the human chemokine receptor CCR5 present on the cell membrane and preventing the interaction of HIV-1 gp 120 and CCR5; this interaction is necessary for CCR5-tropic HIV-1 to enter cells. Selzentry is not recommended in patients with CXCR4-tropic or dual/mixed HIV-1 as it is ineffective in these cases. The Trofile™ test is used to determine if a patient's virus is suitable for a CCR5 co-receptor antagonist therapy; the results of the Trofile test will determine if Selzentry is an appropriate treatment choice for the patient. Also, as compared to treatment with Sustiva® (efavirenz), treatment-naïve adults treated with Selzentry experienced more virologic failure and lamivudine resistance; therefore Selzentry is not recommended for use in treatment-naïve patients.

Program-Specific Information:

Date Range FFS 1-1-2018 to 12-31-2018			
Drug	Claims	Spend	WAC/MAC per unit
SELZENTRY 20 MG/ML SOLN	0	\$0	\$3.37 MAC
SELZENTRY 25MG TABLET	0	\$0	\$4.21 MAC
SELZENTRY 75MG TABLET	0	\$0	\$12.64 MAC
SELZENTRY 150 MG TABLET	33	\$38,923.50	\$15.61 WAC
SELZENTRY 300 MG TABLET	93	\$159,604.96	\$15.61 WAC

- Type of Criteria:** Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit
- Data Sources:** Only administrative databases Databases + Prescriber-supplied

Setting & Population

- Drug for review: Selzentry® (maraviroc)
- Age range: All appropriate MO HealthNet participants aged 2 years and older

Approval Criteria

- Participant has history of positive viral tropism for CCR5-tropic HIV (CPT:87999/22=Trofile test)
- Participant is HIV infected
- Participant is 2 years of age or older
- Participant is not treatment naïve (participant has been on antiretroviral medication before)
- Participant is currently on additional antiretroviral medication besides Selzentry (maraviroc)

Denial Criteria

- Therapy will be denied if no approval criteria met

Required Documentation

Laboratory results:
MedWatch form:

X

Progress notes:
Other:

X

Disposition of Edit

Denial: Exception code "682" (Clinical Edit)

References

- Clinical Care Options. "Tracking Tropism: Epidemiology and Clinical Tools." Postgraduate Institute for Medicine. 2007.
- Selzentry® (maraviroc) [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2018 July.
- IPD analytics. Selzentry (Maraviroc). <https://secure.ipdanalytics.com/User/Pharma/Drug/Selzentry#987fe532-1bd9-413c-9bf5-69051141a1e0>. Accessed April 19, 2019.